Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $1.74 million.

Earnings